EasyCookieInfo

TK-005

Vaccine vs canine Telomerase

  • Well-known and validated target for immunotherapy
  • Overexpressed in >85% of tumors. Potential Universal Antigen!

Where we are:

  • Preclinical studies completed
  • Biomarker assay under advanced development
  • Specialty Oncology Centers / KOLs identified and ready to start

Cancer Targets

  • Lymphoma
  • Sarcoma

tk-004

 

Follow Us on Linkedin

Takis is a biotech dedicated to cancer research. Our primary objective is the development of innovative therapies based on the principle that our immune system can be “instructed” to recognize the tumor and reject it as a foreign entity.